Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Royalty Pharma PLC banner

Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 44.635 USD 1.21% Market Closed
Market Cap: $25.8B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

RPRX Price Targets Summary
Royalty Pharma PLC

Wall Street analysts forecast RPRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RPRX is 48.57 USD with a low forecast of 35.017 USD and a high forecast of 58.8 USD.

RPRX Lowest Forecast
Wall Street Target
35.017 USD
-22% Downside
RPRX Average Forecast
Wall Street Target
48.57 USD
9% Upside
RPRX Highest Forecast
Wall Street Target
58.8 USD
32% Upside
Lowest
Price Target
35.017 USD
22% Downside
Average
Price Target
48.57 USD
9% Upside
Highest
Price Target
58.8 USD
32% Upside
Royalty Pharma PLC Competitors:
Price Targets

Revenue
Forecast

4% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
4% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's revenue is 4%. The projected CAGR for the next 4 years is 16%.

What are analyst estimates?

Operating Income
Forecast

-1% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-31%
Average Miss
-1% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-31%
Average Miss

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's operating income is -1%. The projected CAGR for the next 4 years is 16%.

What are analyst estimates?

Net Income
Forecast

-8% / Year
Past Growth
47% / Year
Estimated Growth
Estimates Accuracy
-64%
Average Miss
-8% / Year
Past Growth
47% / Year
Estimated Growth
Estimates Accuracy
-64%
Average Miss

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's net income is -8%. The projected CAGR for the next 4 years is 47%.

What are analyst estimates?

See Also

Summary
RPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RPRX stock valuation using valuation multiples.
Wall Street Estimates
RPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RPRX's stock price target?
Price Target
48.57 USD

According to Wall Street analysts, the average 1-year price target for RPRX is 48.57 USD with a low forecast of 35.017 USD and a high forecast of 58.8 USD.

What is Royalty Pharma PLC's Revenue forecast?
Projected CAGR
16%

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's revenue is 4%. The projected CAGR for the next 4 years is 16%.

What is Royalty Pharma PLC's Operating Income forecast?
Projected CAGR
16%

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's operating income is -1%. The projected CAGR for the next 4 years is 16%.

What is Royalty Pharma PLC's Net Income forecast?
Projected CAGR
47%

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's net income is -8%. The projected CAGR for the next 4 years is 47%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 315,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.